A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk.
A prospective randomized controlled trial of the effects of vitamin D supplementation on cardiovascular disease risk.
复制标题
DOI：
10.1371/journal.pone.0036617
复制
发表时间：
2012
期刊：
影响因子：
3.7
通讯作者：
Stein JH
中科院分区：
文献类型：
--
作者：
Gepner AD;Ramamurthy R;Krueger DC;Korcarz CE;Binkley N;Stein JH
维生素D（VitD）补充剂已被提倡用于降低心血管风险;然而，支持数据很少。这项研究的目的是确定是否维生素D补充剂降低心血管疾病的风险。在这项前瞻性、随机、双盲、安慰剂对照试验中，血清25-羟基维生素D浓度>10且<60 ng/mL的绝经后妇女被随机分配至维生素D3 2500 IU或安慰剂组，每日一次，持续4个月。主要终点是肱动脉血流介导的血管舒张（FMD）、颈动脉-股动脉脉搏波速度（PWV）和主动脉扩张指数（AIx）的变化。114名受试者的平均（标准差）年龄为63.9（3.0）岁，25-羟基维生素D水平为31.3（10.6）ng/mL。47%的患者存在低VitD（<30 ng/mL），并且与较高的体重指数、收缩压、血糖、CRP和较低的FMD相关（所有p<0.05）。4个月后，维生素D3组的25-羟基维生素D水平增加了15.7（9.3）ng/mL，而安慰剂组增加了-0.2（6.1）ng/mL（p<0.001）。两组间FMD（0.3 [3.4] vs. 0.3 [2.6] %，p = 0.77）、PWV（0.00 [1.06] vs. 0.05 [0.92] m/s，p = 0.65）、AIx（2.7 [6.3] vs. 0.9 [5.6] %，p = 0.10）或CRP（0.3 [1.9] vs. 0.3 [4.2] mg/L，p = 0.97）的变化无显著差异。 多变量模型显示，治疗组和低VitD状态（<30 ng/mL）之间在FMD（p = 0.65）、PWV（p = 0.93）、AIx（p = 0.97）或CRP（p = 0.26）的变化方面没有显著的相互作用。总之，VitD补充剂没有改善内皮功能、动脉硬度或炎症。 这些观察结果不支持使用维生素D补充剂来降低心血管疾病风险。ClinicalTrials.gov NCT 00690417 ClinicalTrials.gov NCT 01049048
Vitamin D (VitD) supplementation has been advocated for cardiovascular risk reduction; however, supporting data are sparse. The objective of this study was to determine whether VitD supplementation reduces cardiovascular risk. Subjects in this prospective, randomized, double-blind, placebo-controlled trial of post-menopausal women with serum 25-hydroxyvitamin D concentrations >10 and <60 ng/mL were randomized to Vitamin D3 2500 IU or placebo, daily for 4 months. Primary endpoints were changes in brachial artery flow-mediated vasodilation (FMD), carotid-femoral pulse wave velocity (PWV), and aortic augmentation index (AIx). The 114 subjects were mean (standard deviation) 63.9 (3.0) years old with a 25-hydroxyvitamin D level of 31.3 (10.6) ng/mL. Low VitD (<30 ng/mL) was present in 47% and was associated with higher body-mass index, systolic blood pressure, glucose, CRP, and lower FMD (all p<0.05). After 4 months, 25-hydroxyvitamin D levels increased by 15.7 (9.3) ng/mL on vitamin D3 vs. −0.2 (6.1) ng/mL on placebo (p<0.001). There were no significant differences between groups in changes in FMD (0.3 [3.4] vs. 0.3 [2.6] %, p = 0.77), PWV (0.00 [1.06] vs. 0.05 [0.92] m/s, p = 0.65), AIx (2.7 [6.3] vs. 0.9 [5.6] %, p = 0.10), or CRP (0.3 [1.9] vs. 0.3 [4.2] mg/L, p = 0.97). Multivariable models showed no significant interactions between treatment group and low VitD status (<30 ng/mL) for changes in FMD (p = 0.65), PWV (p = 0.93), AIx (p = 0.97), or CRP (p = 0.26).In conclusion, VitD supplementation did not improve endothelial function, arterial stiffness, or inflammation. These observations do not support use of VitD supplementation to reduce cardiovascular disease risk. ClinicalTrials.gov NCT00690417 ClinicalTrials.gov NCT01049048
登录
查看更多内容
影响因子：
6.1
作者：
INOUE, M;WAKASUGI, M;ONAYA, T
通讯作者：
ONAYA, T
DOI：
10.2215/cjn.00900208
发表时间：
2008-11-01
影响因子：
9.8
作者：
Andrade, Jason;Er, Lee;Levin, Adeera
通讯作者：
Levin, Adeera
影响因子：
24
作者：
Johnson, Heather M.;Gossett, Linda K.;Piper, Megan E.;Aeschlimann, Susan E.;Korcarz, Claudia E.;Baker, Timothy B.;Fiore, Michael C.;Stein, James H.
通讯作者：
Stein, James H.
影响因子：
4.4
作者：
Boonstra, A;Barrat, FJ;O'Garra, A
通讯作者：
O'Garra, A
影响因子：
--
作者：
Martins, David;Wolf, Myles;Norris, Keith
通讯作者：
Norris, Keith